Top 3 Health Care Stocks That May Rocket Higher In July

Opus Genetics shares are trading higher after the company announced plans to present topline clinical data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 in investor webcast and upcoming Ophthalmology conferences.

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences

Opus Genetics announced plans to present topline clinical data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also present full clinical datasets and additional analyses at several upcoming ophthalmology conferences including Euretina, Retina in Rio, and FLORetina.

Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9

Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ETFull clinical dataset and additional analyses evaluating

RBC Capital Maintains Outperform on Opus Genetics, Lowers Price Target to $9

RBC Capital analyst Lisa Walter maintains Opus Genetics (NASDAQ:IRD) with a Outperform and lowers the price target from $10 to $9.

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.